Amneal Pharmaceuticals (NASDAQ:AMRX) Issues FY 2026 Earnings Guidance

Amneal Pharmaceuticals (NASDAQ:AMRX) updated its FY 2026 earnings guidance on Wednesday. The company provided EPS guidance of 0.950-1.050 for the period, compared to the consensus EPS estimate of 0.950. The company issued revenue guidance of $3.1 billion-$3.2 billion, compared to the consensus revenue estimate of $3.1 billion. Amneal Pharmaceuticals also updated its Q1 2026 guidance to 0.270-0.270 EPS.

Wall Street Analyst Weigh In

AMRX has been the topic of several analyst reports. UBS Group initiated coverage on shares of Amneal Pharmaceuticals in a report on Friday, April 17th. They issued a “buy” rating and a $19.00 target price on the stock. Zacks Research lowered shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 6th. Truist Financial upped their price objective on shares of Amneal Pharmaceuticals from $15.00 to $17.00 and gave the stock a “buy” rating in a research note on Monday, March 2nd. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Amneal Pharmaceuticals in a report on Wednesday, January 21st. Six equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Amneal Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $15.00.

Amneal Pharmaceuticals Stock Performance

Shares of AMRX stock opened at $12.82 on Thursday. The stock’s fifty day moving average is $13.13 and its 200-day moving average is $12.53. Amneal Pharmaceuticals has a 52 week low of $7.02 and a 52 week high of $15.42. The stock has a market capitalization of $4.03 billion, a PE ratio of 55.74 and a beta of 1.32.

Amneal Pharmaceuticals (NASDAQ:AMRX) last issued its quarterly earnings results on Wednesday, April 22nd. The company reported $0.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.15 by $0.11. Amneal Pharmaceuticals had a net margin of 2.39% and a negative return on equity of 228.24%. The business had revenue of $723.00 million for the quarter, compared to the consensus estimate of $709.79 million. Amneal Pharmaceuticals has set its FY 2026 guidance at 0.950-1.050 EPS and its Q1 2026 guidance at 0.270-0.270 EPS. As a group, analysts forecast that Amneal Pharmaceuticals will post 0.91 earnings per share for the current fiscal year.

Key Stories Impacting Amneal Pharmaceuticals

Here are the key news stories impacting Amneal Pharmaceuticals this week:

• Positive Sentiment: Q1 results beat estimates: Amneal reported ~ $0.26–$0.27 EPS (above consensus) and revenue ahead of expectations; management raised Q1 and raised/affirmed FY2026 standalone guidance, supporting upside to 2026 revenue and EPS targets. Amneal Q1 Earnings Beat (Zacks)
• Positive Sentiment: Acquisition to expand biosimilars: Amneal agreed to acquire Kashiv BioSciences in a cash-and-stock deal worth up to $1.1B to build a fully integrated biosimilars platform and target a large biologics loss?of?exclusivity opportunity, which should diversify higher?margin/complex product exposure over time. Amneal to buy Kashiv (Reuters)
• Neutral Sentiment: Management detail and Q&A released: The Q1 2026 earnings call transcript provides additional color on product trends, integration plans for Kashiv, and near?term margin dynamics — useful for assessing execution but not an immediate catalyst by itself. Q1 2026 Earnings Call Transcript (Seeking Alpha)
• Negative Sentiment: Financial/structural risks: Amneal still shows thin net margins and a negative return on equity; the $1.1B deal (cash + stock) and existing leverage raise dilution and credit concerns for some investors, which could pressure the stock despite revenue upside. AMRX Profile & Financial Metrics (MarketBeat)

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of AMRX. Creative Planning increased its stake in shares of Amneal Pharmaceuticals by 61.9% in the 2nd quarter. Creative Planning now owns 23,896 shares of the company’s stock valued at $193,000 after buying an additional 9,136 shares during the period. Cerity Partners LLC lifted its stake in shares of Amneal Pharmaceuticals by 19.1% during the fourth quarter. Cerity Partners LLC now owns 14,443 shares of the company’s stock valued at $182,000 after acquiring an additional 2,318 shares during the period. Corient Private Wealth LLC bought a new position in Amneal Pharmaceuticals in the fourth quarter valued at about $174,000. Fieldview Capital Management LLC bought a new position in Amneal Pharmaceuticals in the fourth quarter valued at about $163,000. Finally, CIBC Bancorp USA Inc. acquired a new stake in Amneal Pharmaceuticals in the third quarter worth about $161,000. Institutional investors own 31.82% of the company’s stock.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.